PMID:
Eur J Clin Invest. 2020 Jan 21:e13201. Epub 2020 Jan 21. PMID: 31960952
Abstract Title:
Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients.
Abstract:
BACKGROUND: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects.MATERIALS AND METHODS: Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double-blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability, and intestinal microbiota were analysed at 0, 30, 45, and 60 days.RESULTS: Percentage decrease from baseline of abdominal pain (-48.8% vs. -3.5%), bloating (-36.35% vs. +7.35%) and severity of disease (-30.1% vs. -0.4%) was significantly (p
Health Time 